| Designations: | A3 | Depositors: | J Blenis |
| Biosafety Level: | 1 | Shipped: | frozen |
| Medium & Serum: | See Propagation | Growth Properties: | suspension |
| Organism: | Homo sapiens (human) | Morphology: | lymphoblast |
| |
| Source: | Cell type: T lymphocyte
Disease: acute T cell leukemia |
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| Related Cell Culture Products |
DNA Profile
(STR): | Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 8,11
D16S539: 11
D5S818: 9
D7S820: 8,10
THO1: 6,9.3
TPOX: 8,10
vWA: 17,18 |
| Gender: | male |
| Comments: | The A3 subclone was derived from a Jurkat cell line obtained from the laboratory of Gerald Crabtree at Stanford University.
The Jurkat cells were treated with Fas Antibody and isolated by limiting dilution to obtain a cell line that had a low spontaneous rate of resistance to Fas-medicated apoptosis. [51530]
The resulting wild-type A3 subclone is very sensitive to Fas-mediated apoptosis.
Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. [51527]
ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks. [51529]
Two of these ICR-191 treated clones have been deposited at the ATCC. They are I 9.2 (ATCC CRL-2571), a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2.1 (ATCC CRL-2572), a clone with a mutation in the adaptor FADD. |
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0C |
| Subculturing: | Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 3 to 5 X 10(5) viable cells/ml. Maintain cultures at cell concentrations between 2 X 10(5) and 2 X 10(6) viable cells/ml.
Medium renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Preservation: | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium): ATCC 30-2001
recommended serum: ATCC 30-2020
derivative: ATCC CRL-2571
derivative: ATCC CRL-2572 |
| References: | 51527: Juo P , et al. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol. 8: 1001-1008, 1998. PubMed:
51529: Juo P , et al. FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ. 10: 797-804, 1999. PubMed:
51530: Juo P , et al. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol. Cell. Biol. 17: 24-35, 1997. PubMed: |
![293T/17 [HEK 293T/17] (人胚肾细胞)](https://p-02.freecchost.com/200x150/www2006/200903020854625225.gif)
![Hep 3B2.1-7 [Hep 3B; Hep-3B; Hep3B]（人肝癌细胞）](https://p-07.freecchost.com/200x150/www2006/200903041610197766.gif)
